| Status: Recommended with restrictions | ||
Ustekinumab (Stelara®) is recommended as an option for restricted use within NHS Wales. Ustekinumab (Stelara®) is licensed for the treatment of moderate to severe plaque psoriasis in children from the age of 6 to 11 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Ustekinumab (Stelara®) is restricted for use for the treatment of severe plaque psoriasis (as defined by a total Psoriasis Area Severity Index [PASI] of 10 or more) in children from the age of 6 to 11 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. |
||
|
||
Medicine details |
||
| Medicine name | ustekinumab (Stelara®) | |
| Formulation | 45 mg and 90 mg concentrate for solution for injection | |
| Reference number | 3687 | |
| Indication | Treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 to 11 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Skin | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended with restrictions | |
| Advice number | 1621 | |
| AWMSG meeting date | 09/11/2021 | |
| Date of issue | 24/11/2021 | |
| Further information See also: |
||